Heart Attack Diagnostics Market was valued at USD 11.01 billion in 2023 and is expected to reach USD 21.38 billion by 2032, growing at a CAGR of 7.64% from 2024-2032.
Heart Attack Diagnostics Market Report provides insights with an in-depth incidence and prevalence study by geographic regions, portraying demographic trends for heart attack occurrence. The report offers diagnostic use trends, portraying regional use trends of ECG, blood biomarker testing (Troponin & CK-MB), and imaging diagnosis. The report also analyzes diagnostic test volume, providing forecasts for the adoption of annual tests and improvements in AI-enabled rapid diagnosis. It gives a detailed healthcare expenditure analysis (2023), breaking down expenditures into government, private insurance, commercial payers, and out-of-pocket expenses, providing a complete financial perspective on heart attack diagnosis globally.
Drivers
The rising Prevalence of Cardiovascular Diseases and the Growing Geriatric Population driving the market growth.
The growing incidence of cardiovascular diseases (CVDs), such as heart attacks, is a major growth driver for the heart attack diagnostics market. CVDs account for about 17.9 million deaths every year, according to the World Health Organization (WHO), and cause almost 32% of total deaths worldwide. The growing geriatric population also adds to this burden, as age is a major risk factor for heart disease. By 2050, there will be 2.1 billion people over the age of 60 worldwide, as predicted by the United Nations. There have been recent breakthroughs in diagnostic technology, including high-sensitivity troponin assays and AI-based ECG systems, that are making early detection more effective. Beckman Coulter gained FDA approval for its Access NT-proBNP assay in May 2024, and this trend is likely to grow, driving the market forward.
Technological Advancements in Cardiac Diagnostic Tools propelling the heart attack diagnostics market.
The heart attack diagnostics market is fueled by ongoing technological innovation across cardiac biomarker testing, imaging modalities, and artificial intelligence-based diagnostic tools. Assays like Roche's Elecsys Troponin T-high sensitive Assay allows early and precise myocardial infarction detection. The application of machine learning and artificial intelligence to ECG analysis is changing the face of diagnostics by lowering false negatives and allowing real-time examination. In August 2024, GE Healthcare also obtained CE mark approval for its AI-powered Vscan Air SL with Caption AI, which increases point-of-care cardiac imaging. Moreover, improved portable and wearable ECG devices enable remote monitoring, enhancing patient outcomes. Such developments, combined with growing R&D expenditure, are anticipated to fuel market growth by delivering quicker, more efficient, and more accessible diagnostic solutions.
Restraint
High Cost of Advanced Diagnostic Technologies and Limited Accessibility restraining the market from growing.
The expense of sophisticated diagnostic equipment is a major constraint in the heart attack diagnostics market, especially in low- and middle-income nations. Cardiac biomarker tests using high-sensitivity biomarkers, artificial intelligence-based ECG devices, and imaging techniques like cardiac MRI and CT scans involve huge capital expenditures on equipment, maintenance, and trained personnel. For instance, the prices of high-sensitivity troponin assays and point-of-care testing machines may be too high for small healthcare centers. Also, rural and developing areas usually do not have access to these sophisticated diagnostic solutions because of poor healthcare infrastructure. As per the WHO, almost 50% of the global population does not have access to basic health services, which further restricts early diagnosis and timely treatment for heart attacks. Without affordable solutions and enhanced accessibility, the growth potential of the market remains curtailed.
Opportunities
The growing integration of artificial intelligence (AI) and point-of-care testing (POCT) in heart attack diagnostics presents a significant opportunity for market expansion.
The increasing adoption of artificial intelligence (AI) and point-of-care testing (POCT) in heart attack diagnosis offers tremendous opportunities for growth in the market. AI-assisted ECG analysis and machine learning allow quicker and more accurate diagnosis of myocardial infarctions, with decreased diagnostic mistakes and enhanced patient outcomes. Players like GE Healthcare and Philips are in the process of integrating AI into their diagnostic platforms to accelerate real-time decision-making. Further, handheld and portable POCT devices enable quick biomarker testing in emergencies, which cuts the time to diagnosis to a great extent. The growing need for decentralized healthcare options, especially in remote and underdeveloped areas, also hastens the integration of these technologies. With increased investments in POCT and AI, the market is likely to see enhanced accessibility, efficiency, and patient-centric care.
Challenges
One of the key challenges in the heart attack diagnostics market is the variability in test sensitivity and specificity across different diagnostic modalities.
Variability in test sensitivity and specificity between diagnostic modalities is one of the main challenges faced in the market for heart attack diagnostics. Although there has been great progress with high-sensitivity troponin assays in terms of improved accuracy of detection of myocardial infarction, differences in biomarker thresholds between manufacturers can cause inconsistency in results. For instance, research has indicated that troponin levels can vary with patient demographics, underlying conditions, and assay sensitivity, resulting in false positives or negatives at times. Likewise, ECG interpretation can differ based on the clinician's level of expertise, resulting in misdiagnosis. The absence of standardization of diagnostic protocols and interpretation criteria continues to be an issue, especially in emergency departments where rapid decision-making is paramount. This problem demands worldwide harmonization of diagnostic standards, enhanced training of clinicians, and ongoing technology improvement in testing accuracy.
By Test
The blood test segment dominated the heart attack diagnostics market with a 55.26% market share in 2023 as a result of its high specificity, quick detection rate, and extensive usage in emergency environments. Blood tests, especially those identifying cardiac biomarkers such as troponin and CK-MB, form a pivotal part of diagnosing myocardial infarction through the detection of heart muscle injury. Of these, high-sensitivity troponin assays have emerged as the gold standard since they allow for early identification of even small cardiac damage, enhancing patient outcomes. Growing implementation of point-of-care blood testing in emergency departments and ambulatory care facilities and advancements in technology concerning assay sensitivity and specificity further consolidated the dominance of the segment. Furthermore, regulatory clearances, including the FDA clearance of Beckman Coulter's Access NT-proBNP assay in 2024, have added to the importance of blood testing in heart attack diagnosis.
The CK-MB segment is witness to grow at the fastest rate during the forecast period owing to its increasing use as a surrogate biomarker for troponin testing, especially in reinfarction cases. Creatine kinase-MB (CK-MB) is a standard marker of myocardial injury and is usually employed when troponin results are inconclusive. New studies indicate that CK-MB testing can be useful in assessing the degree and timing of heart muscle damage, particularly in the case of recurrent cardiac events. The increasing need for fast and affordable cardiac biomarker tests in developing economies is also driving the growth of the segment. In addition, improvements in automated immunoassay platforms, combined with growing awareness regarding the need for multi-biomarker testing for holistic cardiac evaluation, are likely to propel the use of CK-MB diagnostics in the forecast years.
By End-use
The Ambulatory Surgical Centers (ASCs) segment dominated the heart attack diagnostics market with a 53.29% market share in 2023 as more cardiac diagnostic procedures moved out of the hospital and into the outpatient environment. ASCs provide inexpensive, effective, and convenient diagnostic services, taking pressure off emergency departments and inpatient hospital facilities. With improvements in point-of-care diagnostics and handheld diagnostic devices, ASCs have emerged as centers of choice for immediate cardiac biomarkers testing, such as troponin and CK-MB testing. Moreover, favorable reimbursement rules and shorter waiting times for patients have also played a significant role in the broad-based adoption of ASCs for the diagnosis of heart attacks. The increasing number of cardiovascular disorders, along with patient preference for minimally invasive and rapid diagnostic tests, also supported the supremacy of the segment in 2023.
The Ambulatory Surgical Centers segment is anticipated to grow the most in the forecast period, fueled by the continued development of outpatient care models and the growing adoption of sophisticated diagnostic technologies. Governments and providers are committing funds to ASCs to improve early detection of cardiac disease and lower readmission rates. The increasing use of portable electrocardiograms (ECGs), quick blood biomarker tests, and artificial intelligence (AI)-driven diagnostic devices in ASCs is also driving their growth further. ASCs are also providing major cost benefits over hospital-based diagnostics, thus emerging as a desirable choice in developed and emerging economies alike. As regulatory authorities continue to encourage outpatient care with beneficial policies and insurance coverage, the ASC segment is expected to grow significantly in the next few years.
North America dominated the heart attack diagnostics market with 38.56% market share in 2023, because of its established healthcare infrastructure, high burden of cardiovascular diseases, and heavy investments in medical technology. It has a high number of heart attacks, and the American Heart Association (AHA) estimates that nearly 805,000 individuals in the U.S. suffer from heart attacks annually. Furthermore, the dominant position of major players like Abbott, Siemens Healthineers, and GE Healthcare ensures ongoing innovation in diagnostic equipment, such as high-sensitivity troponin assays and AI-based ECG devices. Favorable reimbursement policies, widespread use of point-of-care testing in emergency departments, and government programs for lowering cardiovascular mortality further consolidate North America's position in this market.
Asia Pacific is the fastest growing region during the forecast period with 8.75% CAGR in the heart attack diagnostics market, fueled by a fast-growing aging population, increasing burden of cardiovascular disease, and growing healthcare expenditure. China, India, and Japan are seeing an upsurge in heart disease cases as a result of lifestyle changes, increased obesity, and growing rates of diabetes and hypertension. The increasing utilization of advanced diagnostic technologies, combined with the government-led efforts to enhance the accessibility of healthcare, is driving growth in the market. Also, medical tourism in India and Thailand is encouraging demand for cost-efficient and high-quality diagnostics. The rise of point-of-care diagnostics and AI-based diagnostics, combined with increasing awareness regarding early diagnosis, is likely to drive market growth in the region in the years to come.
Some of the major key players in the Heart Attack Diagnostics Market
Abbott Laboratories (ARCHITECT STAT High Sensitivity Troponin-I Assay, i-STAT System)
Beckman Coulter (Access hsTnI Assay, DxI 800 Immunoassay System)
Bio-Rad Laboratories, Inc. (Cardiac Marker Control, Liquichek Cardiac Markers Plus Control)
Siemens Healthineers (ADVIA Centaur TnI-Ultra Assay, Atellica IM 1300 Analyzer)
GE Healthcare (MAC 2000 Resting ECG System, CardioSoft Diagnostic System)
Hitachi Medical Systems (HI VISION Avius Ultrasound System, Noblus Portable Ultrasound)
Schiller AG (CARDIOVIT AT-102 G2 ECG Device, MAGLIFE RT-1 Patient Monitor)
Koninklijke Philips N.V. (PageWriter TC70 Cardiograph, IntelliVue MX700 Patient Monitor)
F. Hoffmann-La Roche Ltd. (Elecsys Troponin T-high sensitive Assay, Cobas h 232 POC System)
Bayer AG (CONTOUR Blood Glucose Monitoring System, Multistix 10 SG Reagent Strips)
bioMérieux, Inc. (VIDAS Troponin I Ultra Assay, VIDAS NT-proBNP Assay)
Danaher Corporation (Triage Cardiac Panel, Dimension EXL with LM Integrated Chemistry System)
Life Sign LLC (Status DS Troponin I Test, Status First Aid Rapid Test)
Toshiba Corporation (Aquilion ONE CT Scanner, Aplio i-series Ultrasound)
FUJIFILM Holdings (FDR Go PLUS Portable X-ray System, Arietta 850 Ultrasound)
Midmark Corporation (IQecg Digital ECG, IQvitals Zone Vital Signs Monitor)
Hill-Rom Services (Welch Allyn) (CP 150 Resting ECG, Connex Spot Monitor)
Canon Medical Systems Corporation (Aquilion Prime SP CT System, Aplio i800 Ultrasound)
Bionet Co., Ltd. (CardioTouch 3000 ECG, BM3 Patient Monitor)
Edwards Lifesciences Corporation (FloTrac Hemodynamic Monitoring System, ClearSight System)
Suppliers (These suppliers play a crucial role in the availability and performance of heart attack diagnostic products worldwide.)
Thermo Fisher Scientific
Merck KGaA
Agilent Technologies
PerkinElmer Inc.
Sysmex Corporation
Randox Laboratories
Sekisui Diagnostics
Trinity Biotech
Diazyme Laboratories, Inc.
QuidelOrtho Corporation
May 2024 – Beckman Coulter, a worldwide leader in clinical diagnostics, has obtained U.S. Food and Drug Administration (FDA) clearance for its Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay. Compatible with the DxI 9000 Immunoassay Analyzer, the assay provides results within less than 11 minutes, greatly enhancing diagnostic efficiency. It serves a vital purpose in the determination of heart failure severity, risk stratification, and assisting in the diagnosis of acute heart failure in emergency conditions.
August 2024 – GE HealthCare has received CE mark clearance for its Vscan Air SL wireless handheld ultrasound system with Caption AI, an artificial intelligence (AI)-based software intended for fast cardiac evaluation at the point of care. The company also has introduced ECG-less Cardiac CT scanning on the Revolution Apex platform, allowing clinicians to acquire cardiac images without using patients' electrocardiogram (ECG) signals. Both innovative technologies will be featured during the European Society of Cardiology (ESC) Congress in London from August 30 to September 2, 2024.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 11.01 billion |
| Market Size by 2032 | US$ 21.38 billion |
| CAGR | CAGR of 7.64% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Test (Electrocardiogram, Blood Test [Troponin, CK-MB], Others) • By End-use (Hospitals, Ambulatory Surgical Centers, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories, Inc., Siemens Healthineers, GE Healthcare, Hitachi Medical Systems, Schiller AG, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Bayer AG, bioMérieux, Inc., Danaher Corporation, Life Sign LLC, Toshiba Corporation, FUJIFILM Holdings, Midmark Corporation, Hill-Rom Services (Welch Allyn), Canon Medical Systems Corporation, Bionet Co., Ltd., Edwards Lifesciences Corporation, and other players. |
Ans: The Heart Attack Diagnostics Market is expected to grow at a CAGR of 7.64% during 2024-2032.
Ans: The Heart Attack Diagnostics Market was USD 11.01 billion in 2023 and is expected to Reach USD 21.38 billion by 2032.
Ans: The rising Prevalence of Cardiovascular Diseases and the Growing Geriatric Population driving the market growth.
Ans: The “Blood Test” segment dominated the Heart Attack Diagnostics Market.
Ans: North America dominated the Heart Attack Diagnostics Market in 2023
Table of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Diagnostic Utilization Trends (2023), by Region
5.3 Diagnostic Test Volume, by Region (2020-2032)
5.4 Healthcare Spending on Heart Attack Diagnostics, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Heart Attack Diagnostics Market Segmentation, by Test
7.1 Chapter Overview
7.2 Electrocardiogram
7.2.1 Electrocardiogram Market Trends Analysis (2020-2032)
7.2.2 Electrocardiogram Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Blood Test
7.3.1 Blood Test Market Trends Analysis (2020-2032)
7.3.2 Blood Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Troponin
7.3.3.1 Troponin Market Trends Analysis (2020-2032)
7.3.3.2 Troponin Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 CK-MB
7.3.4.1 CK-MB Market Trends Analysis (2020-2032)
7.3.4.2 CK-MB Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Others
7.4.1 Others Market Trends Analysis (2020-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Heart Attack Diagnostics Market Segmentation, by End User
8.1 Chapter Overview
8.2 Hospitals
8.2.1 Hospitals Market Trends Analysis (2020-2032)
8.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Ambulatory Surgical Centers
8.3.1 Ambulatory Surgical Centers Market Trends Analysis (2020-2032)
8.3.2 Ambulatory Surgical Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2020-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Heart Attack Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.2.4 North America Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.2.5.2 USA Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.2.6.2 Canada Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.2.7.2 Mexico Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Heart Attack Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.1.5.2 Poland Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.1.6.2 Romania Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Heart Attack Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.4 Western Europe Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.5.2 Germany Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.6.2 France Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.7.2 UK Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.8.2 Italy Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.9.2 Spain Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Healthcare Predictive Analytic Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.12.2 Austria Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Heart Attack Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.4.4 Asia Pacific Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.4.5.2 China Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.4.5.2 India Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.4.5.2 Japan Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.4.6.2 South Korea Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.2.7.2 Vietnam Healthcare Predictive Analytic Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.4.8.2 Singapore Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.4.9.2 Australia Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Heart Attack Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.1.4 Middle East Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.1.5.2 UAE Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Heart Attack Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.2.4 Africa Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Heart Attack Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.6.4 Latin America Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.6.5.2 Brazil Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.6.6.2 Argentina Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.6.7.2 Colombia Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Heart Attack Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Heart Attack Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Beckman Coulter
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Bio-Rad Laboratories, Inc.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Siemens Healthineers
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 GE Healthcare
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Hitachi Medical Systems
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Schiller AG
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Koninklijke Philips N.V.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 F. Hoffmann-La Roche Ltd.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Bayer AG
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusio
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Test
Electrocardiogram
Blood Test
Troponin
CK-MB
Others
By End-use
Hospitals
Ambulatory Surgical Centers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Cleanroom Technologies Market Size was valued at USD 8.1 billion in 2023 and is expected to reach USD 14.76 billion by 2032 and grow at a CAGR of 6.8%.
The Oncology Information Systems Market Size was valued at USD 3.1 Billion in 2023 and is expected to reach USD 6.1 Billion by 2032, growing at a CAGR of 7.84% over the forecast period 2024-2032.
Postpartum Products Market Size was valued at USD 2.53 billion in 2023 and is expected to reach USD 4.47 billion by 2032, growing at a CAGR of 6.54% over the forecast period 2024-2032.
Comprehensive Metabolic Panel Testing Market, valued at USD 11.18 Billion in 2023, is forecasted to grow at a 9.12% CAGR, reaching USD 24.48 Billion by 2032.
The Medical Billing Market was valued at USD 15.43 billion in 2023 and is expected to reach USD 41.32 billion by 2032, growing at a CAGR of 11.58% over the forecast period 2024-2032.
The Cosmetic Dentistry Market was valued at USD 37.16 billion in 2023 and is expected to reach USD 115.09 billion by 2032, growing at a CAGR of 13.21% from 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
